Article Information
History
- July 25, 2019.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ana Miar1,
- Esther Arnaiz2,
- Esther Bridges1,
- Shaunna Beedie1,
- Adam P Cribbs3,
- Damien J. Downes4,
- Robert Beagrie4,
- Jan Rehwinkel5 and
- Adrian L. Harris1,‡
- 1Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
- 2Onkologia Molekularraren Taldea, Onkologia Arloa, Molecular Oncology Group, Biodonostia Instituto de Investigación Sanitaria, Spain
- 3Botnar Research Center, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, NIHR Oxford BRU, University of Oxford, OX3 7DQ, UK
- 4Medical Research Council (MRC) Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK
- 5Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK
- ↵‡To whom correspondence should be addressed: Adrian L. Harris Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, OX3 9DS, UK. E-mail: adrian.harris{at}oncology.ox.ac.uk. Phone: +44 (0)1865 222457 (PA).